载脂蛋白E基因多态性对他汀类药物调脂消斑的影响  

Effects of apolipoprotein E polmorphism on efficacy of Tating drugs in treating coronary heart disease

作　　者：张莉莉[1] 吕安林[1] 贾国良[1] 王海昌[1] 

机构地区：[1]第四军医大学西京医院心血管内科,陕西西安710033

出　　处：《第四军医大学学报》2004年第11期1029-1031,共3页Journal of the Fourth Military Medical University

摘　　要：目的 :研究载脂蛋白E(apoE)基因多态性对冠心病他汀类药物调脂消斑的影响 .方法 :采用PCR RELP法测定1 2 1例冠心病患者 (均经冠脉造影证实 )的基因型 .常规检查其中 95例在口服他汀类药物 (阿托伐他汀 )前及 0 .5a后的血总胆固醇 (TC)、三酰甘油 (TG)、低密度脂蛋白胆固醇 (LDLC)和高密度脂蛋白胆固醇 (HDLC)水平 .冠心病狭窄诊断标准按QCA方法确定 .结果 :发现 5种基因型 ,分别为E2 / 2 ,E2 / 3,E3/ 3,E3/ 4和E4 / 4 .E2 / 2 +E2 / 3及E3/ 3型的血脂TC ,LDLC ,HDLC及冠脉狭窄疗效比E3/ 4 +E4 / 4变化显著 ,二者有统计学差异 (P <0 .0 1 ) .结论 :apoE基因多态性与调脂及冠脉狭窄的治疗相关 (P <0 .0 5 ) .疗效按E2 / 2 +E2 / 3,E3/ 3,E3/ 4 +E4 /AIM: To explore the relationship between apolipoprotein E (apoE) polmorphism and the efficacy of Tating drugs in regulating lipid and eliminating atherosclerosis in treating coronary heart disease. METHODS: One hundred and twenty one coronary heart disease (CHD) patients’ genotypes were detected by PCR RELP and the serum lipid levels were measured by routine methods. The diagnostic standards for coronary atherosclerotic stenosis were established by QCA. RESULTS: Five genotypes of apoE E2/2, E 2/3, E3/3, E3/4 and E4/4 were detected and the plasma lipid level total cholesterol (TC) and low density lipoprotein (Ldl c) and high density lipoprotein (Hdlc) markedly decreased ( P < 0.01) in patients with CHD. Among the 5 genotypes, apo E2/2 + E2/3 and E3/3 had significantly better efficacy than apo E3/4+E4/4 ( P < 0.05) . CONCLUSION: Our results suggest that apo E gene polmorphism is closely associated with plasma lipid regulation and coronary atherosclerosis elimination.

关 键 词：冠心病 载脂蛋白E 基因多态性 血脂水平 冠脉狭窄 

分 类 号：R541.4[医药卫生—心血管疾病]